Vanguard Fiduciary Trust
JBIO

Vanguard Fiduciary Trust’s Jade Biosciences JBIO Stock Holding History

Vanguard Fiduciary Trust’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.77M Buy
304,867
+85,370
+39% +$1.78M ﹤0.01% 2019
2026
Q1 		$3.08M Buy
+219,497
New +$3.18M ﹤0.01% 2340

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust's JBIO Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Jade Biosciences (JBIO) stake by 39% in Q2 2026, buying an estimated $1.78M and bringing the position to 304,867 shares worth $6.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2019.

Vanguard Fiduciary Trust first reported a position in JBIO in Q1 2026 and has held it in 2 quarters since. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Vanguard Fiduciary Trust held 304,867 shares of Jade Biosciences worth $6.77M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 85,370 Jade Biosciences shares in Q2 2026, an estimated $1.78M.
  • Jade Biosciences made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2019 holding.
  • Vanguard Fiduciary Trust first reported a position in Jade Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.